30-Day Trial of Oral Valtrex or Valtrex Plus Aspirin on Shedding of HSV DNA in Tears and Saliva of Volunteers
Status:
Unknown status
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether oral Valtrex alone or in combination with
aspirin will reduce the shedding of herpes simplex virus DNA in the tears and saliva from
volunteers with no evidence of ocular herpes infection. The secretion of virus into the tears
and saliva might make people more susceptible to virus infection in the future if their
immune system becomes deficient. The study will also try to determine if there is a
correlation between shedding of viral DNA and herpes virus antibodies in serum and to
determine if subjects are carriers of a special form of a gene in their blood cells, the
presence of which may suggest the possibility of an increased susceptability to herpes and to
Alzheimer's disease and heart disease.